.15-.20 is actually being conservative. We're talking about a growing company with 20M in revs per year with an intent to go to NASDAQ and complete M&A.
Everything is screaming undervalued independent of technicals.
There hasn't been another OTC stock like this so it's very hard for people to see where this is going on a holistic level.
OTC stocks get a bad rep, and understandably so, but OTC for RXMD is just a stepping stone to where they are actually headed and focused on.
People should be stocking up on RXMD like it was the only water left in a catastrophic drought.
On the technicals side we ran from .005 - .054.
This time we've started with a base 3-4 times that level (.015-.02).
So it's easy to see that we go to at least .10 from that base, and quite frankly .20 is also very possible.
Finally, look at how long the run lasted years ago.
October 2015 - March 2016.
That's 4-5 months...
So we are easily going to be in this uptrend until end of April.
And that's when the company will probably announce M&A.
Management is very knowledgeable in securities.
They know when to make the deals happen and when to announce them.
Market Data 
Markets 
AI
